These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27572830)

  • 1. A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.
    Tsai M; Chrones L; Xie J; Gevorkyan H; Macek TA
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3787-3795. PubMed ID: 27572830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events.
    Goldsmith P; Affinito J; McCue M; Tsai M; Roepcke S; Xie J; Gertsik L; Macek TA
    Drugs R D; 2017 Dec; 17(4):631-643. PubMed ID: 29103081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia.
    Macek TA; McCue M; Dong X; Hanson E; Goldsmith P; Affinito J; Mahableshwarkar AR
    Schizophr Res; 2019 Feb; 204():289-294. PubMed ID: 30190165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.
    Macek TA; Suzuki K; Asin K; Kimura H
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):524-532. PubMed ID: 32598478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects.
    Yurgelun-Todd DA; Renshaw PF; Goldsmith P; Uz T; Macek TA
    Psychopharmacology (Berl); 2020 Feb; 237(2):317-328. PubMed ID: 31773211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor.
    Takano A; Stenkrona P; Stepanov V; Amini N; Martinsson S; Tsai M; Goldsmith P; Xie J; Wu J; Uz T; Halldin C; Macek TA
    Neuroimage; 2016 Nov; 141():10-17. PubMed ID: 27423256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
    Suzuki K; Harada A; Shiraishi E; Kimura H
    J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.
    Suzuki K; Harada A; Suzuki H; Miyamoto M; Kimura H
    Neuropsychopharmacology; 2016 Aug; 41(9):2252-62. PubMed ID: 26849714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor.
    Harada A; Suzuki K; Kamiguchi N; Miyamoto M; Tohyama K; Nakashima K; Taniguchi T; Kimura H
    PLoS One; 2015; 10(3):e0122197. PubMed ID: 25815469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain PET measurement of PDE10A occupancy by TAK-063, a new PDE10A inhibitor, using [11 C]T-773 in nonhuman primates.
    Takano A; Stepanov V; Nakao R; Amini N; Gulyás B; Kimura H; Halldin C
    Synapse; 2016 Jun; 70(6):253-63. PubMed ID: 26878349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia.
    Walling DP; Banerjee A; Dawra V; Boyer S; Schmidt CJ; DeMartinis N
    J Clin Psychopharmacol; 2019; 39(6):575-582. PubMed ID: 31688451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
    Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
    J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phosphodiesterase 10A selective inhibitor, TAK-063, induces c-Fos expression in both direct and indirect pathway medium spiny neurons and sub-regions of the medial prefrontal cortex in rats.
    Nakatani A; Nakamura S; Kimura H
    Neurosci Res; 2017 Dec; 125():29-36. PubMed ID: 28687229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
    Harada A; Suzuki K; Kimura H
    J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.
    Sakurai Y; Nishimura A; Kennedy G; Hibberd M; Jenkins R; Okamoto H; Yoneyama T; Jenkins H; Ashida K; Irie S; Täubel J
    Clin Transl Gastroenterol; 2015 Jun; 6(6):e94. PubMed ID: 26111126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.
    Suzuki K; Kimura H
    CNS Neurosci Ther; 2018 Jul; 24(7):604-614. PubMed ID: 29318783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.
    Fossler MJ; Schmith V; Greene SA; Lohmer L; Kramer MS; Arscott K; James IE; Demitrack MA
    CNS Drugs; 2020 Aug; 34(8):853-865. PubMed ID: 32676977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
    Esfandiari E; Chen M; Smithson G; Blair D; Faessel H; Wagner J; Mclean L; Fedyk ER
    Clin Transl Sci; 2021 May; 14(3):820-828. PubMed ID: 33650758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.
    Davis J; Hackman F; Ndongo MN; Choo H; Lewis D; Tawadrous M; Goodrich J; Langdon G
    Clin Ther; 2010 Oct; 32(11):1889-95. PubMed ID: 21095483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.